These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34157885)

  • 1. Semaglutide for Weight Loss.
    Carris NW; Dietrich EA
    Ann Pharmacother; 2022 Feb; 56(2):224-226. PubMed ID: 34157885
    [No Abstract]   [Full Text] [Related]  

  • 2. Semaglutide for weight loss.
    Ojeniran M; Dube B; Paige A; Ton J; Lindblad AJ
    Can Fam Physician; 2021 Nov; 67(11):842. PubMed ID: 34772713
    [No Abstract]   [Full Text] [Related]  

  • 3. Glycaemic control and weight loss with semaglutide in type 2 diabetes.
    Madsbad S; Holst JJ
    Lancet Diabetes Endocrinol; 2017 May; 5(5):315-317. PubMed ID: 28385658
    [No Abstract]   [Full Text] [Related]  

  • 4. Once-Weekly Semaglutide with Lifestyle Intervention Results in Clinically Significant Weight Loss.
    Chang RS; Hu JR; Yeh HC
    J Gen Intern Med; 2022 May; 37(7):1824-1826. PubMed ID: 35230621
    [No Abstract]   [Full Text] [Related]  

  • 5. Semaglutide for Weight Loss: Was It Worth the Weight?: Erratum.
    Cardiol Rev; 2023 Jan-Feb 01; 31(1):57. PubMed ID: 36469361
    [No Abstract]   [Full Text] [Related]  

  • 6. In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER.
    Bekiari E; Karagiannis T; Tsapas A
    Ann Intern Med; 2018 Apr; 168(8):JC46. PubMed ID: 29677253
    [No Abstract]   [Full Text] [Related]  

  • 7. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
    Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K;
    N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists.
    Crabtree TSJ; Adamson K; Reid H; Barnes D; Sivappriyan S; Bickerton A; Gallen IW; Field BCT; Idris I; Ryder REJ;
    Diabetes Obes Metab; 2022 Jul; 24(7):1398-1401. PubMed ID: 35322528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.
    Cowart K
    Ann Pharmacother; 2020 May; 54(5):478-485. PubMed ID: 31744308
    [No Abstract]   [Full Text] [Related]  

  • 10. Oral semaglutide in Japanese versus non-Japanese patients with type 2 diabetes.
    Scheen AJ
    Lancet Diabetes Endocrinol; 2020 May; 8(5):350-352. PubMed ID: 32333865
    [No Abstract]   [Full Text] [Related]  

  • 11. Wegovy (semaglutide): a new weight loss drug for chronic weight management.
    Singh G; Krauthamer M; Bjalme-Evans M
    J Investig Med; 2022 Jan; 70(1):5-13. PubMed ID: 34706925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States.
    Hunt B; Hansen BB; Ericsson Å; Kallenbach K; Ali SN; Dang-Tan T; Malkin SJP; Valentine WJ
    Adv Ther; 2019 Dec; 36(12):3483-3493. PubMed ID: 31650514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Add-on value of tirzepatide versus semaglutide.
    Scheen AJ
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):377-378. PubMed ID: 35468323
    [No Abstract]   [Full Text] [Related]  

  • 14. In poorly controlled type 2 diabetes, oral semaglutide was noninferior to liraglutide for reducing HbA1c.
    Lipscombe LL
    Ann Intern Med; 2019 Sep; 171(6):JC29. PubMed ID: 31525763
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.
    Rosenstock J; Allison D; Birkenfeld AL; Blicher TM; Deenadayalan S; Jacobsen JB; Serusclat P; Violante R; Watada H; Davies M;
    JAMA; 2019 Apr; 321(15):1466-1480. PubMed ID: 30903796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In type 2 diabetes, tirzepatide reduced HbA
    Gandhi GY
    Ann Intern Med; 2021 Nov; 174(11):JC127. PubMed ID: 34724396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
    Davies M; Færch L; Jeppesen OK; Pakseresht A; Pedersen SD; Perreault L; Rosenstock J; Shimomura I; Viljoen A; Wadden TA; Lingvay I;
    Lancet; 2021 Mar; 397(10278):971-984. PubMed ID: 33667417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
    Johansen P; Sandberg A; Capehorn M
    Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis.
    Mishriky BM; Cummings DM; Powell JR; Sewell KA; Tanenberg RJ
    Diabetes Metab; 2019 Apr; 45(2):102-109. PubMed ID: 30243806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral glucagon-like peptide-receptor agonists (GLP1RA) counseling: comparison with insulin counseling.
    Kalra S; Kalhan A; Berard L
    Postgrad Med; 2020 Nov; 132(8):663-666. PubMed ID: 32781867
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.